EnGen Bio has seen its shares rise for the second consecutive day following news of an expanded supply of its blood cancer diagnostic panel.
As of 1:56 PM on July 22, EnGen Bio's stock was trading at 2,370 won, up 545 won (29.86%) from the previous trading day. This marks a continuation of the stock's rise to the daily price limit.
The surge in stock price is attributed to the announcement that the 'HEMEaccuTest' blood cancer diagnostic panel has begun being supplied to Bundang Seoul National University Hospital.
The company stated, "The blood cancer diagnostic business is expanding its clinical application scope, focusing on major general hospitals in South Korea," and confirmed the start of supply to Bundang Seoul National University Hospital.
EnGen Bio is currently supplying the HEMEaccuTest to over 20 major general hospitals in South Korea, including Seoul St. Mary's Hospital and the main branch of Seoul National University Hospital. This supply will not only expand domestic clinical references but also broaden its supply network in international markets such as Singapore, Vietnam, Colombia, Germany, and Romania.
The blood cancer panel business continues to show growth. According to EnGen Bio, the blood cancer panel business has grown at an average annual rate of 36% over the past five years, with domestic sales increasing by 38% and international sales by 102% in the first quarter of this year compared to the same period last year.
EnGen Bio emphasized, "We will continue to expand our supply to major hospitals in South Korea and target the global market based on our comprehensive diagnostic portfolio that covers everything from blood cancer diagnosis to relapse monitoring."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.